

해외 바이오의약품 임상 현황 ('24년 1월 4주)

한국바이오의약품협회, 2024.01.30.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.  
- 출처: ClinicalTrials.gov  
- 모니터링 기간: 2024.01.22.~2024.01.28.  
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06225596</a>	Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Drug: BT8009 Drug: Pembrolizumab Drug: Gemcitabine + cisplatin Or carboplatin Drug: Avelumab	BicycleTx Limited	Phase 2 Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06225596</a>
<a href="#">NCT06190093</a>	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	Biological: bevacizumab Biological: ranibizumab	Outlook Therapeutics, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06190093</a>
<a href="#">NCT06151847</a>	Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	Procedure: Biospecimen Collection Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Biological: Interleukin-2 Biological: Lifileucel Procedure: Magnetic Resonance Imaging Procedure: Multigated Acquisition Scan Procedure: Tumor Resection	University of Kansas Medical Center National Cancer Institute (NCI) Iovance Biotherapeutics, Inc.	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06151847</a>
<a href="#">NCT04466475</a>	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT04466475</a>
<a href="#">NCT06220669</a>	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	Drug: LY3541860 Drug: Placebo	Eli Lilly and Company	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06220669</a>
<a href="#">NCT06121297</a>	RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus	Biological: CABA-201	Cabaletta Bio	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06121297</a>
<a href="#">NCT06179511</a>	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06179511</a>
<a href="#">NCT06083675</a>	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	Drug: Semaglutide Drug: Empagliflozin Drug: Metformin	Novo Nordisk A/S	Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06083675</a>

○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06179511</a>	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06179511</a>

○ 중국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06199336</a>	Safety and Efficacy Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines	Biological: JHM03 Biological: BOTOX췎 Biological: Placebo	JHM BioPharma (Tonghua) Co. , Ltd.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06199336</a>
<a href="#">NCT06215846</a>	A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors	Biological: BioTTT001 injection	Beijing Bio-Targeting Therapeutics Technology Co., Ltd	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06215846</a>

# 해외 바이오의약품 임상 현황 ('24년 1월 4주)

한국바이오의약품협회, 2024.01.30.

○ 중국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06187597</a>	Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)	Drug: S-1 Drug: Toripalimab Radiation: Intensity-modulated radiotherapy	Sun Yat-sen University Nanfang Hospital, Southern Medical University Zhujiang Hospital Fifth Affiliated Hospital, Sun Yat-Sen University Xiangya Hospital of Central South University Wuhan University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06187597</a>
<a href="#">NCT06114056</a>	A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)	Biological: JWK007 Single intravenous infusion administration	West China Hospital	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06114056</a>
<a href="#">NCT06228560</a>	Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment	Biological: LP-003 Biological: Placebo Biological: Omalizumab	Longbio Pharma	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06228560</a>
<a href="#">NCT06186414</a>	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC	Drug: SIM0237 Drug: SIM0237 and BCG	Jiangsu Simcere Pharmaceutical Co., Ltd. Shanghai Xianxiang Medical Technology Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06186414</a>
<a href="#">NCT06179511</a>	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06179511</a>

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06179511</a>	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06179511</a>